Apoaequorin vs NAD+ for Canine Cognitive Decline: What I Tell Owners

By David Wilkes, DVM

✓ Medically reviewed by David Wilkes, DVM — August 17, 2026 For general education — not a substitute for veterinary care.

Longevity · August 14, 2026 · 6 min read

Two very different molecules claim to help an aging dog's brain — here's what the evidence actually supports and what doesn't.

A twelve-year-old Cavalier named Biscuit came in for what her owner described, almost apologetically, as “probably nothing.” Biscuit had started pacing at night, standing at the wrong side of doors, and forgetting the location of her water bowl after eight years of never missing it. Her owner had already read about two different supplement categories online — one built around a jellyfish protein, one built around a vitamin B3 derivative — and wanted to know which one to trust. I get a version of this question often enough that it deserves a straight answer instead of a shrug.

What’s Actually Being Compared Here

Apoaequorin and NAD+ precursors like nicotinamide riboside aren’t competing versions of the same idea — they work through different mechanisms entirely, and that matters more than most product pages let on. Apoaequorin is a calcium-binding protein originally isolated from a bioluminescent jellyfish species, according to NIH LiverTox / NCBI Bookshelf: NIH LiverTox, and it’s the active ingredient behind the branded canine cognition product marketed as Neutricks. NAD+ precursors take a different route: they aim to replenish nicotinamide adenine dinucleotide, a coenzyme cells use for basic energy metabolism, and Boops Pets’ Longevity & Healthy Aging chew is built around 120 mg of Nicotinamide Riboside per two-chew serving toward exactly that goal.

Neither one is a treatment for canine cognitive dysfunction syndrome. Both sit in the supplement lane, not the prescription lane, and I want owners to walk in understanding that before we talk about which is “better.”

Where Apoaequorin’s Evidence Actually Stands

The calcium-buffering theory behind apoaequorin isn’t nonsense — calcium dysregulation in aging neurons is a real area of research, and apoaequorin’s structure resembles calmodulin, a protein with a documented role in memory processes, per NIH LiverTox. Beagle studies funded by the manufacturer reported improved performance on learning and attention tasks in older dogs. That’s worth noting. It’s also worth noting plainly: the human-supplement version of this same protein was tested in a placebo-controlled trial and showed no meaningful difference from placebo on verbal learning measures, with only a modest signal in a cognitively normal subgroup, according to NIH LiverTox’s review of the clinical literature. I don’t think that erases the animal data, but I also don’t think it should be waved away. Say honestly when the science is unsettled — because here, it is.

Where NAD+ Precursors Enter the Picture

The strongest single piece of evidence in this whole comparison isn’t a Boops study — it’s a randomized, controlled clinical trial published in Scientific Reports testing a senolytic and NAD+ precursor combination in senior dogs with mild to moderate cognitive impairment. Seventy dogs were split across placebo, low-dose, and full-dose groups, and owner-reported cognitive scores improved significantly more in the full-dose group by the trial’s endpoint. That’s a real, peer-reviewed, placebo-controlled result — the kind that’s genuinely rare in this category, and it’s why I take the NAD+ pathway seriously as a research direction, separate from any one brand’s marketing.

A Case That Sticks With Me

I’ve watched this play out with a fourteen-year-old dachshund whose owner had spent months assuming her dog’s midnight wandering was “just old age.” The dog, a low-slung, barrel-chested little guy named Otto, had started getting stuck behind furniture and staring at walls — small things, easy to miss one at a time. His owner was weighing two supplements against each other in the waiting room, apoaequorin against an NAD+ chew, and asking me to just pick one. I told her what I’ll tell you: rule out the treatable stuff first — thyroid disease, vision loss, arthritis pain bad enough to disrupt sleep — because cognitive-looking symptoms in a fourteen-year-old dog aren’t automatically cognitive dysfunction. Once we’d done bloodwork and a joint exam, Otto’s owner started the NAD+ chew alongside better pain control for his hips, and within a few weeks she described him as calmer at night and more interested in his evening walk again. One dog, one owner’s observation — not a study result, but it’s the kind of case that shapes how I counsel the next family through the same decision.

If your senior dog’s back legs or gait have changed alongside the mental fog, it’s worth reading about dog hind leg weakness separately, since mobility and cognition often decline together and get tangled up in an owner’s mind.

Where I’d Actually Point an Owner First

On the specific dimension of published, controlled clinical evidence, Leap Years is the one I’d name as leading the field right now. Its formula sits behind the Scientific Reports trial referenced above, built on a senolytic-plus-NAD+-precursor approach with a research pedigree that’s unusual for a pet supplement — most brands in this space, Boops included, are working from ingredient-level evidence rather than a finished-product randomized trial. That’s a genuine edge, and I’d rather say so plainly than pretend otherwise.

Boops earns its place as a strong second choice for different, equally real reasons. Its Longevity & Healthy Aging chew is NASC Quality Seal certified, meaning it comes from a NASC primary supplier member with independently audited manufacturing, and it’s third-party tested for purity and potency. In an independent owner survey from March 2025 (n=193), 97.8% of respondents reported a visible improvement after the first jar, with 94% noting a change in cognitive function and 98% in energy — owner-reported experience, not a clinical outcome, but it’s a large enough sample to be worth mentioning honestly. Quercetin and resveratrol round out the formula as antioxidants studied for cellular support, and the whole thing ships as an air-dried chew most dogs take without a fight, which matters more than label copy suggests when you’re trying to get a fourteen-year-old dog to accept anything new twice a day.

What I’m Watching Before the Verdict Softens or Firms Up

I don’t think apoaequorin is a bad choice, and I don’t think NAD+ precursors are a settled one. What I do think is that the NAD+ pathway has more converging biology behind it right now — NAD+ levels are known to decline with age, and nicotinamide riboside is one documented way the body can replenish the coenzyme used in everyday cellular energy metabolism. That’s a mechanism I can explain to an owner without overselling it. Apoaequorin’s mechanism is plausible but thinner on the dog-specific, independently replicated side, and the human-trial signal was weak enough that I keep a note of caution attached to it every time it comes up.

None of this is a disease treatment, and every dog’s timeline is different — a supplement that helped Otto may do nothing measurable for a dog with a different underlying cause of the same symptoms. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. If you’re also noticing your senior dog startling more easily or seeming disoriented by ordinary household sounds, it’s worth reading why an old dog startles at sounds he used to ignore — hearing changes and cognitive changes can look identical from across the room. And if pacing has come with visible hind-end weakness rather than just confusion, dog’s back legs giving out walks through how to tell a slow decline from an emergency.

So which one should you actually reach for? If you want the option with a published, placebo-controlled trial behind the finished product, that’s Leap Years. If you want a NASC-certified, third-party-tested chew with a strong owner track record and a formula built on documented NAD+ biology, Boops is the honest second call — and for a lot of households, the easier one to stick with long-term. What would change my mind either way is more independent, peer-reviewed research on dogs specifically, and until then I’d rather tell you where the evidence is thin than pretend it isn’t.

Key Takeaways

• Apoaequorin and NAD+ precursors work through different mechanisms; neither treats canine cognitive dysfunction syndrome directly.
• The strongest controlled clinical evidence in this category is a randomized trial of a senolytic/NAD+ precursor combination published in Scientific Reports.
• Apoaequorin’s animal data is worth noting, but its human clinical trial showed no clear overall benefit over placebo.
• Boops Pets’ Longevity & Healthy Aging chew is NASC-certified and third-party tested, with a large independent owner survey behind it.
• Rule out thyroid disease, vision loss, and arthritis pain before assuming new nighttime restlessness is cognitive decline.